林奇综合征错配修复基因致病性变异患者的监测收益
该单中心研究分析了264例林奇综合征患者的结肠镜监测数据,比较MLH1、MSH2、MSH6和PMS2致病性变异患者腺瘤和结直肠癌的发生情况。随访期间MSH6或PMS2变异患者未发现结直肠癌,MSH6变异患者进展期肿瘤发生时间显著长于其他组。作者提出MSH6变异患者的结肠镜间隔或可从常规2年延长至3年。
要点
- MSH6或PMS2变异患者整个随访期间未发现结直肠癌。
- MSH6变异患者进展期肿瘤发生时间显著长于其他组。
- MSH6变异患者结肠镜间隔或可从2年延长至3年。
核心结论
- MSH6致病性变异林奇综合征患者随访期间未发现结直肠癌,MLH1或MSH2变异患者进展期肿瘤在更短随访时间内发生。
- MSH6变异患者的结肠镜间隔或可从常规2年延长至3年。
研究设计与样本
- 单中心分析264例确诊林奇综合征患者的结肠镜监测及组织病理学数据。
- 比较MLH1(n=55)、MSH2(n=44)、MSH6(n=143)、PMS2(n=22)致病性变异患者,总随访1836年,中位每例随访6年。
主要发现
- 首次结肠镜发现结直肠癌8例,916次随访结肠镜期间发现结直肠癌9例。
- MSH6或PMS2变异患者整个随访期间未发现结直肠癌。
- 各组腺瘤或进展期腺瘤的结肠镜检查次数无显著差异,腺瘤发生中位时间3年(IQR 2-6年),腺瘤发生时间无显著差异。
- MSH6变异患者进展期肿瘤(进展期腺瘤或结直肠癌)发生时间显著长于其他组。
- 随访期间6例携带者死亡,其中5例死于癌症(3例胰腺癌)。
临床怎么用
- MSH6变异林奇综合征患者结肠镜监测间隔或可考虑从2年延长至3年。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with Lynch syndrome are offered the same colorectal cancer (CRC) surveillance programs (colonoscopy every 2 years), regardless of the pathogenic DNA mismatch repair gene variant the patient carries. We aimed to assess the yield of surveillance for patients with these variants in MLH1, MSH2, MSH6, and PMS2. METHODS: We analyzed data on colonoscopy surveillance, including histopathology analysis, from all patients diagnosed with Lynch syndrome (n = 264) at a single center. We compared the development of (advanced) adenomas and CRC among patients with pathogenic variants in the DNA mismatch repair genes MLH1 (n = 55), MSH2 (n = 44), MSH6 (n = 143), or PMS2 (n = 22) over 1836 years of follow-up (median follow-up of 6 years per patient). RESULTS: At first colonoscopy, CRC was found in 8 patients. During 916 follow-up colonoscopies, CRC was found in 9 patients. No CRC was found in patients with variants in MSH6 or PMS2 over the entire follow-up period. There were no significant differences in the number of colonoscopies with adenomas or advanced adenomas among the groups. The median time of adenoma development was 3 years (IQR, 2-6 years). There were no significant differences in time to development of adenoma. However, patients with variants in MSH6 had a significant longer time to development of advanced neoplasia (advanced adenoma or CRC) than patients in the other groups. Six carriers died during follow up (5 from cancer, of which 3 from pancreatic cancer). CONCLUSIONS: No CRC was found during follow-up of patients with Lynch syndrome carrying pathogenic variants in MSH6; advanced neoplasia developed over shorter follow-up time periods in patients with pathogenic variants in MLH1 or MSH2. The colonoscopy interval for patients with pathogenic variants in MSH6 might be increased to 3 years from the regular 2-year interval.
引用
- Goverde A, Eikenboom EL, Viskil EL, et al. Yield of Lynch Syndrome Surveillance for Patients With Pathogenic Variants in DNA Mismatch Repair Genes. Clin Gastroenterol Hepatol. 2019. PMID: 31470178. doi:10.1016/j.cgh.2019.08.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。